10:05 AM EDT, 05/12/2026 (MT Newswires) -- AstraZeneca (AZN) said Tuesday phase 3 trial results showed that its investigational drug eneboparatide significantly normalized serum calcium and achieved independence from active vitamin D and oral calcium supplements in adults with hypoparathyroidism.

The investigational drug met its composite primary endpoint as 31.1% of treated patients achieved normalization of albumin-adjusted serum calcium levels and independence from oral supplements at week 24, compared with 5.9% of the patients in the placebo group, the company said.

The trial also met all key secondary endpoints, including the normalization of urinary calcium excretion in patients with hypercalciuria at baseline, according to a statement.

Eneboparatide was well tolerated with a consistent overall safety profile over 52 weeks of treatment, the statement said.

Price: 183.52, Change: +1.65, Percent Change: +0.91